Genome-wide association study of treatment response to venlafaxine XR in generalized anxiety disorder
Jeesun Jung1, Elisabeth A Tawa2, Christine Muench2
1Division of Intramural Clinical and Biological Research, National Institute of Alcohol Abuse and Alcoholism, Bethesda, MD, United States.
Abstract:
We conducted the first genome-wide association study (GWAS) in Generalized Anxiety Disorder (GAD) to identify potential predictors of venlafaxine XR treatment outcome. Ninety-eight European American patients participated in a venlafaxine XR clinical trial for GAD, with Hamilton Anxiety Scale (HAM-A) response/remission at 24 weeks as the primary outcome measure. All participants were genotyped with the Illumina PsychChip, and 266,820 common single nucleotide polymorphisms (SNPs) were analyzed. Although no SNPs reached genome-wide significance, 8 SNPs were marginally associated with treatment response/remission and HAM-A reduction at week 12 and 24 (p<0.00001). Several identified genes may indicate markers crossing neuropsychiatric diagnostic categories.
More Related Videos
08:33Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
Published on: January 5, 2024
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
Related Concept Videos
Generalized Anxiety Disorder
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Anxiety: Overview
Individuals with anxiety often experience a range of physical and emotional symptoms, including sweating, trembling, tachycardia, and disturbances in sleep patterns. These symptoms vary in intensity and frequency but are generally disruptive and distressing.
Factors Affecting Drug Response: Overview
